“The biggest problem is that we don’t know how to fix it,” said Dr. Jonathan Schatz, a professor of medicine at Harvard Medical School and director of the biopirus program at Harvard T.H. Chan School of Public Health.
“We don’t have any good, high-quality data.”
Schatz was one of the first researchers to identify the toxins, which are often found in seafood but also have been implicated in human illnesses like Lyme disease.
The problem is the toxic compounds have been found in seawater, but scientists don’t yet know how they get there.
The biopiral is a type of bacteria that grows on fish guts and is resistant to most antibiotics.
Schatz and colleagues have been studying biopiruads for years, but their research has focused on isolating and isolating their genes to see how they can be used to treat disease.
“There are lots of different things that could work in the lab to create this compound, but there are also a lot of challenges,” he said.
“It’s a long process, and there’s no cure.
It’s a hard problem to solve.”
Biopiras can be found in many marine environments, including in the seas of California and the Caribbean.
But unlike other toxins, they are highly toxic.
Schatsch and his colleagues have shown that biopircs can bind to and kill bacteria in marine life and in the oceans.
This kills the organisms, but the toxin doesn’t cause any death to the organisms.
In addition, they also have a long half-life, meaning the toxin is toxic for a long time.
Schamps said this is important because the biopols could be used as a tool to protect marine ecosystems from harmful bacteria and to kill the organisms they infect.
The toxin has also been linked to an increased risk of Lyme disease, which affects up to 1.6 million Americans.
“What we are seeing in the Lyme disease data is that the rate of illness has increased, which is very troubling,” Schatz said.
It also has been linked with increased risk for cancers of the liver, kidney and pancreas.
“The longer that it lasts, the more likely that there are going to be a number of cases, which will be more lethal to humans,” Schamps told The Hill.
“And we don�t know what the long-term consequences are for people.
There are a lot more unanswered questions than what we know now.”
The biopol is being tested in a lab in Boston, Massachusetts.
Schitz said he expects the new compound will be available in the next two years.
The drug will also be tested in the field, Schatz added.
The goal is to see if the compound can work in animals.
“For humans, we have a lot to learn about how to get it to work in a living organism,” he told The Post.
“But we know how it works in a laboratory.”
The FDA is also investigating whether the drug is safe for humans and animals.
Schanks said that is likely to take at least five years.
If approved, the drug would be the first drug to target the toxin.
The FDA has also launched a clinical trial to test the drug in humans and is considering whether to put it on the market.